Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZYC300
- Development stage
- Phase 1
- Lead developer
- Eisai
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intramuscular
01
Overview
ZYC300 is an investigational anticancer DNA vaccine consisting of a plasmid encoding an inactivated form of the carcinogen-activating enzyme cytochrome P450 1B1 (CYP1B1), encapsulated within biodegradable poly-DL-lactide-coglycolide microparticles. The vaccine is designed to stimulate T lymphocyte responses against CYP1B1, which is highly expressed in various tumor cells but not in most normal tissues. By inducing immune sensitivity to this tumor-associated antigen, ZYC300 aims to promote antitumor immunity. It was developed for the treatment of multiple solid tumors, including breast, colon, ovarian, prostate, and renal cancers. The drug reached Phase I clinical trials but development was discontinued prior to further advancement[1][2][3].
- Other names
- ZYC 300ZYC300ZYC-300
02
Targets
CYP1B1 (Cytochrome P450 1B1)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on ZYC300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZYC300.